BioCryst Pharmaceuticals Rating Lowered to Neutral at Zacks

Home › BioCryst Pharmaceuticals Rating Lowered to Neutral at Zacks

They currently have a $2.00 price target on the stock. A number of other analysts have also recently weighed in on BCRX.

07.11	Lawsuit over FDA's regulatory approval process for carbadox dismissed
07.11	Hurricane Rafael Graphics
07.11	Hurricane Rafael Forecast Discussion Number 16
07.11	Hurricane Rafael Wind Speed Probabilities Number 16
07.11	Hurricane Rafael Forecast Advisory Number 16
07.11	Hurricane Rafael Public Advisory Number 16
07.11	Summary for Hurricane Rafael (AT3/AL182024)
07.11	Tropical Depression Fourteen-E Graphics
More »

je.st